Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Interest Expenses (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Interest Expenses for 4 consecutive years, with $909000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest Expenses fell 23.16% year-over-year to $909000.0, compared with a TTM value of $3.9 million through Sep 2025, down 17.99%, and an annual FY2024 reading of $4.6 million, down 12.68% over the prior year.
  • Interest Expenses was $909000.0 for Q3 2025 at Atara Biotherapeutics, down from $972000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.4 million in Q3 2023 and bottomed at $4000.0 in Q1 2022.
  • Average Interest Expenses over 4 years is $878066.7, with a median of $1.0 million recorded in 2024.
  • The sharpest move saw Interest Expenses skyrocketed 33300.0% in 2023, then decreased 23.16% in 2025.
  • Year by year, Interest Expenses stood at $117000.0 in 2022, then surged by 905.13% to $1.2 million in 2023, then dropped by 13.52% to $1.0 million in 2024, then dropped by 10.62% to $909000.0 in 2025.
  • Business Quant data shows Interest Expenses for ATRA at $909000.0 in Q3 2025, $972000.0 in Q2 2025, and $1.0 million in Q1 2025.